Business Wire

AÉMA-GROUPE

30.9.2021 14:15:05 CEST | Business Wire | Press release

Share
Aéma Groupe Concludes the Acquisition of Aviva France, Becoming One of the Top 5 French Insurers

On 30 September 2021, Aéma Groupe acquired Aviva France, after obtaining the necessary authorisations from the regulatory authorities. This large-scale operation places Aéma Groupe in the 5th position of the French insurance industry. It concretises the original ambition of Macif and Aésio Mutuelle, founders of Aéma Groupe, to build a leading mutual insurance group that now protects over 11 million French people.

‘The creation of Aéma Groupe was the culmination of the ambition of two companies, Aésio Mutuelle and Macif, to join forces to build a large-scale mutual insurance group capable of offering the broadest possible protection to its policyholders, both today and tomorrow. The acquisition of Aviva France is the first phase in this process. This transaction, which was completed in less than a year and ahead of schedule, demonstrates our ability to build a strong and innovative player that meets the growing needs of society as a whole’. - Adrien Couret - Managing Director of Aéma Groupe.

An acquisition that confirms the relevance of the Aéma Groupe model

Thanks to its economic significance and strategic importance, this transaction brings Aviva France under the French mutual insurance umbrella. Aéma Groupe thereby demonstrates its ability to expand and serve a wider range of policyholders (individuals, professionals, self-employed persons, companies) with a comprehensive range of solutions. This multi-brand, multi-network, multi-business group is strengthening its positions in all areas of insurance thanks to its complementary expertise. As a resolutely mutualist group, it will also make the voice of its members and customers heard in the public debate on social issues relating to protection and retirement.

‘We are very proud to welcome this fine company as the third pillar of Aéma Groupe, alongside Macif and Aésio. With Aviva France, we are creating a leading French mutual insurance group. From now on, Aviva France, supported by its 4,500 employees, will keep growing within our common structure. It will accomplish this while retaining its identity and its specific characteristics, with the same determination to provide increasingly relevant and sustainable insurance solutions to its 3 million policyholders, including the 760,000 members of AFER’. - Pascal Michard , Chairperson of Aéma Groupe.

New management for Aviva France

Following the acquisition, Aviva France has formed its new board of directors, which has appointed Jean-Philippe Dogneton as Chairperson and Philippe-Michel Labrosse as Chief Executive Officer of Aviva France.

‘In addition to enriching our diversity, the arrival of Aviva France within our group will enhance our diversity and gives us new responsibilities vis-à-vis the policyholders, the members and the clients we deal with on a daily basis. This acquisition will enhance the synergies of skills and expertise and the mutual know-how to enrich our offers and services. We are extremely proud and happy to welcome the Aviva France teams who share our values of solidarity and commitment’. - Jean-Philippe Dogneton , Assistant Managing Director of Aéma Groupe, Managing Director of Macif and new Chairperson of Aviva France

I would like to thank the Board of Directors of Aviva France for trusting me to anchor the company to Aéma Groupe, its new parent company, and to keep it on the path to success with the support of all its employees, networks and partners’. Philippe-Michel Labrosse – Managing Director of Aviva France.

Aviva France will be rebranded with a gradual roll-out.

This acquisition involved Lazard as lead M&A advisor, Credit Suisse as financing and M&A advisor, White & Case LLP as legal advisor, Kearney for strategy, EY for accounting and financial analysis, Prim'Act for actuarial services, and Fromont Briens for employment law.

–––––––––––––––––––––––––––––––––––––––––––––––––

Key figures:

  • 14.5 billion euro in turnover;
  • 18,000 employees;
  • 11 million policyholders;
  • Property & Casualty: 5 billion euro in premium income;
  • Health & Personal Protection: 3 billion euro in premium income;
  • Life business: 6.5 billion euro in premium income;
  • Assets under management: 195 billion euro.

Leading positions in the business lines:

  • 5th largest insurance company in France;
  • 2nd largest player in home and car insurance;
  • 3rd largest mutual group in individual and group health;
  • 5th largest player in life insurance;
  • 6th largest player in asset management.

About Aéma Groupe
Aéma is the mutual insurance group formed by the merger of Aésio Mutuelle and Macif.
With more than 11 million policyholders, it employs 18,000 people
and generates a turnover of 14.5 billion euros in France.
Aéma Groupe envisions a fairer and more humane world every day by making foresight a central part of the relationship with its members, policyholders and corporate clients.
Find out more: aemagroupe.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye